Clinical risk and monitoring essentials of tonifying Chinese patent medicine
- VernacularTitle:扶正类中成药临床使用风险及监护要点分析
- Author:
Huan SUN
1
;
Qiaoli ZHAI
1
;
Jie XU
1
;
Bing LOU
1
;
Pijun GONG
1
;
Beiwei XIN
1
Author Information
1. Dept. of Pharmacy，Shanghai Seventh People’s Hospital，Shanghai 200137，China
- Publication Type:Journal Article
- Keywords:
tonifying traditional Chinese medicine;
clinical risk;
pharmaceutical care;
safe use of drugs;
special populations
- From:
China Pharmacy
2025;36(23):2974-2977
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the clinical risks and monitoring essentials associated with tonifying Chinese patent medicine. METHODS The varieties of tonifying Chinese patent medicines listed in the National Basic Drug List （2024 edition） were counted. Package inserts were collected using software such as “Dingxiangyuan” and then classified and organized according to criteria such as “drug name”“ingredients”“contraindications”“precautions”“drug interactions”. The names of traditional Chinese medicine （TCM） decoction pieces were standardized in accordance with the Chinese Pharmacopoeia （2020 edition） and other relevant standards； literature was reviewed to compile information on TCM decoction pieces that required caution/were contraindicated in special populations， as well as tonifying Chinese patent medicines and their related clinical applications. Then， a database for tonifying Chinese patent medicines was ultimately established by relying on the hospital’s internal information system， so as to conduct an in-depth exploration of the clinical usage risks and key monitoring points of tonifying Chinese patent medicines. RESULTS A total of 222 tonifying traditional Chinese medicines were evaluated. Contraindications or requirements for cautious use were identified in 91 （40.99%） for hepatic or renal impairment， 9 （4.05%） for hypertension， and 8 （3.60%） for pediatric patients， and 109 （49.10%） were designated as contraindicated or requiring caution for athletes. CONCLUSIONS Although tonifying Chinese patent medicines are indicated for deficiency patterns， their use is accompanied by measurable clinical risk， especially in individuals with hepatic or renal compromise who are prone to adverse reactions.
